@article { author = {Rahimi, Hossein and Jafarian, Amir Hosein and Samadi, Alireza and Meamar, Bahram}, title = {Evaluation of BCL6 and MUM1 Expression in Patients with Diffuse Large B Cell Lymphoma (DLBCL) and Their Correlation with Staging and Prognosis of the Disease}, journal = {Journal of Patient Safety & Quality Improvement}, volume = {3}, number = {1}, pages = {198-200}, year = {2015}, publisher = {Mashhad University of Medical Sciences}, issn = {2345-4482}, eissn = {2345-4490}, doi = {10.22038/psj.2015.3814}, abstract = {Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin Lymphoma (NHL) which includes about (25%) of the cases. Patients with DLBCL have a rapidly growing mass that is located in the neck or abdominal region. Multiple Myeloma Oncogene (MUM1) has an important role in lymphoid cell differentiation. MUM1/IRF4 is as oncogene related to myeloma and translocation (p25; q32), t (6; 14) and leads to a change in the heavy chain of Immunoglobulin (IGH). BCL6 exists in approximately (100%) of follicular cell cancer cases, (100%) of Burkitt lymphoma, (80%) of large B-cell lymphoma, and in more than (80%) of nodular lymphocytic Hodgkin lymphoma cases. BCL6 is related to cancers with a high proliferation cell index. In some studies BCL6 is expressed as a prognostic factor in LBCL patients}, keywords = {Diffuse large B-cell lymphoma,MUM1,BCL6}, url = {https://psj.mums.ac.ir/article_3814.html}, eprint = {https://psj.mums.ac.ir/article_3814_6825530c5a8c66f49e20f7286b63d927.pdf} }